TAK-721 Karma is a Biatch For Leadership

Quote
It really is amazing how abbvie keeps tacking additional indications onto humira for conditions I've never even heard of (HS?), yet we can't even get budesonide approved in a slurry, even though specialty pharmacies have been compounding these slurries off-label for years. Wow. Where's the launch excellence? I would expect to see accountability in the new year.
 








anonymous said:
It really is amazing how abbvie keeps tacking additional indications onto humira for conditions I've never even heard of (HS?), yet we can't even get budesonide approved in a slurry, even though specialty pharmacies have been compounding these slurries off-label for years. Wow. Where's the launch excellence? I would expect to see accountability in the new year.
Click to expand...
Launch excellence? Accountability? Are you smoking crack… There is no launch excellence or accountability here. That’s why we’re in the mess we’re in.
 




anonymous said:
It really is amazing how abbvie keeps tacking additional indications onto humira for conditions I've never even heard of (HS?), yet we can't even get budesonide approved in a slurry, even though specialty pharmacies have been compounding these slurries off-label for years. Wow. Where's the launch excellence? I would expect to see accountability in the new year.
Click to expand...

What? "we can't even get budesonide approved in a slurry"? What makes you think it was a good idea to begin with? Approve something that's already generic to become branded $$$$ (seen that movie before..Colcrys)
Glad the FDA shut it down! Even though the response letter said go do another study, they were basically saying go efff yourself Takeda, you're stupid for bringing this up here! Now we (Takeda) look like complete idiots in front of our GI's telling them the news, they knew all along it would have selfishly been a nice to have, but not worth the crazy ass expense of bringing a generic into a branded $$$$ product. Takeda brings great repackaged generics to market to further our leadership, reputation, and trust with the GI community! Nice!!!
 




anonymous said:
What? "we can't even get budesonide approved in a slurry"? What makes you think it was a good idea to begin with? Approve something that's already generic to become branded $$$$ (seen that movie before..Colcrys)
Glad the FDA shut it down! Even though the response letter said go do another study, they were basically saying go efff yourself Takeda, you're stupid for bringing this up here! Now we (Takeda) look like complete idiots in front of our GI's telling them the news, they knew all along it would have selfishly been a nice to have, but not worth the crazy ass expense of bringing a generic into a branded $$$$ product. Takeda brings great repackaged generics to market to further our leadership, reputation, and trust with the GI community! Nice!!!
Click to expand...

I appreciate your post but this was a Shire asset acquired through the acquisition so that all but negates your entire post.
 








anonymous said:
I appreciate your post but this was a Shire asset acquired through the acquisition so that all but negates your entire post.
Click to expand...

I'm well aware it was a Shire asset, yet Takeda continued pushing it forward for well over a year, talking it up via "EoE DSE" (should be outlawed - phony wink/nod promotion), and in the process damaged any reputation remaining with GI's by trying to repackage a generic as a branded.
 








anonymous said:
I'm well aware it was a Shire asset, yet Takeda continued pushing it forward for well over a year, talking it up via "EoE DSE" (should be outlawed - phony wink/nod promotion), and in the process damaged any reputation remaining with GI's by trying to repackage a generic as a branded.
Click to expand...

This is 100% accurate, so sketchy.
 




anonymous said:
I'm well aware it was a Shire asset, yet Takeda continued pushing it forward for well over a year, talking it up via "EoE DSE" (should be outlawed - phony wink/nod promotion), and in the process damaged any reputation remaining with GI's by trying to repackage a generic as a branded.
Click to expand...

You're hung up on the branded vs generic thing. Btw, I agree with you on that. However, this is not another colcrys saga. Tak721 is all about the delivery.... That's it. That's the differentiator, the value. Forget that it's budesonide, it doesn't matter. The unmet need is in the delivery via the slurry, the inhaled steroids don't work for EoE bc most of the drug winds up in the lungs and not the esophagus. Enter tak721, no need to find an spp that will compound a viscous slurry. It's already done, way more convenient for patients and providers. There's a bigger issue here, and it has nothing to do with budesonide.
 




anonymous said:
You're hung up on the branded vs generic thing. Btw, I agree with you on that. However, this is not another colcrys saga. Tak721 is all about the delivery.... That's it. That's the differentiator, the value. Forget that it's budesonide, it doesn't matter. The unmet need is in the delivery via the slurry, the inhaled steroids don't work for EoE bc most of the drug winds up in the lungs and not the esophagus. Enter tak721, no need to find an spp that will compound a viscous slurry. It's already done, way more convenient for patients and providers. There's a bigger issue here, and it has nothing to do with budesonide.
Click to expand...
It doesn’t matter this damn thing was doomed from the start. Half of the problem is that it had Shires name on it and that company was a piece of crap and everybody knew it. TAKEDA is no better when it comes to launches. It’s all about FDA friendliness and we don’t have it. Do you think Pfizer is so great? Half of the shit they brought to market is some reconstituted bullshit from another company, they either bought the company, co-promoted, or took old crap and gave it a new name. It’s all a bunch of BS
 












Top Bottom
Back
Quote